Wendy Young
Vice President, Discovery Chemistry at Genentech
Ensuring that we have a culture that supports innovation and provides access to the most cutting edge approaches and tools is key. Just as important is that we continue to recruit and retain the brightest chemists on the planet.
LINKS
Genentech Inc.
1 DNA Way
MS#18
South San Francisco, CA 94080
Phone: 650-467-7945
young.wendy@gene.com\ |
Wendy Young, Ph.D., Director, Discovery Chemistry, Genentech
Wendy B. Young has nineteen years of industrial drug discovery experience, having led discovery efforts at both small biotech firms (Axys/Celera and Scios: 1995-2006) and larger companies (Genentech/Roche: 2006-present). Wendy is currently Director of Medicinal Chemistry at Genentech, where she is a leader of project teams and directs a large group of medicinal chemists.
These teams have produced multiple clinical candidates, from a variety of target classes, currently under clinical evaluation in a range of indications.
She was recently elected as Vice Chair of the ACS Medicinal Chemistry (ACS MEDI) Division which will culminate in her being Chair of the Division in 2017.
Wendy received her Ph.D. from Princeton University under the direction of E.C. Taylor and carried out Postdoctoral Studies at Memorial Sloan Kettering Cancer Center with Professor Samuel Danishefsky.
Wendy is listed as an inventor or author on over 65 patent and research publications and has given presentations at many national and international meetings.
"We all know friends and family members that have suffered with serious illness. It can be devastating. My goal, alongside my colleagues, is to discover agents that will treat these patients. The motto "patients are waiting" really hits home with everyone."
I was drawn to join Genentech, in 2006, because of its reputation for doing excellent science and employing strong teamwork. At Genentech, any team member with a compelling idea gets a chance to be heard and access to the resources to move their idea forward. The organization is also very nimble and open-minded to incorporate processes to accelerate discovery and development.
Today, I am Vice President of Discovery Chemistry, overseeing a highly talented and experienced group of medicinal, computational and analytical chemists. These Genentech chemists are integral on our project teams to innovate and discover the next generation of medicines to treat patients in need.
What excites me the most is that, at Genentech, we have the brightest people, tools, and know-how to continue to make huge strides in solving complex biological and medical issues. It is a huge opportunity and responsibility to shape the future treatments for patients in need.
FEATURED PUBLICATION
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nature Chemical Biology, 2011, ISSN: 1552-4469 Di Paolo, J.; Huangm T.; Balazs, M.; Barbosa, J.; Barck, K.; Bravo, B.;Carano, R.; Darrow, J.; Davies, D.; DeForge, L.; Diehl, L.; Ferrando,R.; Gallion, S.; Giannetti, A.; Gribling, P.; Hurez, V.; Hymowitz, S.; Jones, R.; Kropf, J.; Lee, W.; Maciejewski, P.; Mitchell, S.; Rong, H.; Staker, B.; Whitney, A.; Yeh, S.; Young, W.; Yu, C.; Zhang, J.; Reif,K.; Currie, K. View Abstract on PubMedExperience
Associate Director, Medicinal Chemistry
Scios, a Johnson & Johnson Co.
Postdoctoral Fellow
Sloan-Kettering Cancer Center
Advisor: Samuel Danishefsky
Design and total synthesis of the anti-cancer agent Taxol®
Education
Princeton University
PhD, Chemistry
Advisor: E.C. Taylor
Dissertation: Design and Synthesis of Folate Analogs as Novel Anti-Cancer Agents
Wake Forest University
BA, MS, Chemistry
Advisor: Huw M.L. Davies:
Thesis: Novel Entry into the Tropane Alkyloid Ring System Via Reactions of Vinyl Carbenoids and Pyrroles"
- Sloan Kettering Cancer Center, American Cancer Society, Postdoctoral Fellow – 1995
- Princeton University, Ph.D. Chemistry – 1993
- Wake Forest University, B.A./M.S. Chemistry, cum laude – 1988
- AWARDS
-
- Elected Chair of National ACS MEDI – 2017
- Elected Program Chair of National ACS MEDI – 2015-2016
- Elected Vice Chair of National ACS MEDI – 2014
- American Cancer Society Postdoctoral Fellowship – 1993-1995
- H. W. Dodds - Princeton University Honorific Fellowship, Top Thesis Award – 1993
- Josephine de Karman Fellowship – 1992
- ACS Graduate Fellowship sponsored by Lilly Research Laboratories – 1991-1992
- Department of Education Graduate Fellowship – 1990
- BA/MS Chemistry Scholarship, Wake Forest University – 1988
-
Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834
Bioorganic & medicinal chemistry letters, 2015, ISSN: 0960-894X View on PubMed -
3-Heterocyclyl quinolone inhibitors of the HCV NS5B polymerase
Bioorganic and Medicinal Chemistry Letters, 1 January 2012, v22, p300-304, ISSN: 0960-894X. View on PubMed -
Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor
Drug metabolism and disposition: the biological fate of chemicals, {Drug-Metab-Dispos}, 8 Jul 2011 (epub: 8 7 2011), ISSN: 1521-009X. View on PubMed -
Pyrazolopyridine Inhibitors of B-Raf<sup>V600E</sup>. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.
ACS Medicinal Chemistry Letters, 2011, ISSN: 1948-5875 View on PubMed -
Quinolones as HCV NS5B Polymerase Inhibitors
Bioorganic & Medicinal Chemistry Letters, 2011, View on PubMed -
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Nature Chemical Biology, 2010, ISSN: 1552-4469 View on PubMed
Influential Women 2015: Wendy Young
Wendy Young, Ph.D.
Vice president, discovery chemistry, Genentech
Education: B.A., M.S., chemistry, Wake Forest University; Ph.D., chemistry, Princeton University.
Proudest professional accomplishment: I was team leader for seven years on an important drug development project where there’s a lot of industry competition. We had to overcome many obstacles but I believed in the project and in the science and wouldn’t give up. We ultimately discovered the root of the problem and presented the data to regulators, and they allowed us to move the medicine into the clinic. Our team emerged as a really tight-knit group because we wouldn’t give up as we had a strong passion for the end goal. It was a great example of how perseverance is key.
How to help women in business advance: What I’ve learned is that to succeed, you must have achievement. You’ll get more visibility by racking up achievements. Don’t be distracted by sideline activities because it takes away time and energy from things that will really matter. Be brave. Speak up. Figure out how to find your voice.
Dream super power: To not need sleep.
Surprising fact about you: I love to hula hoop!
.................................................................................
Executive Committee
Regular Executive Committee Members
Program Chair 2015-2016
Wendy B. Young, Ph.D. Vice President, Discovery Chemistry Genentech Inc. 1 DNA Way MS#18 South San Francisco, CA 94080 Phone: 650-467-7945 young.wendy@gene.com ..................................................................................
MEDICINAL & BIOLOGICAL CHEMISTRY
https://www.utoledo.edu/pharmacy/depts/mbc/MAGSS/keynote.html
Guest Speaker and Panelist
Dr. Wendy Young, Director of Medicinal Chemistry, Genentech; Vice Chair, ACS Medicinal Chemistry Division
Wendy B. Young has twenty years of drug discovery experience, having led discovery efforts at both small biotech firms (Axys/Celera and Scios: 1995-2006) and larger companies (Genentech/Roche: 2006-present). Wendy is currently Director of Medicinal Chemistry at Genentech, where she is a leader of project teams and directs a large group of medicinal chemists. These teams have produced multiple clinical candidates, from a variety of target classes, currently under clinical evaluation in a range of indications. Wendy received her Ph.D. from Princeton University in chemistry under the direction of E.C. Taylor and was an American Cancer Society Postdoctoral Fellow at Memorial Sloan Kettering Cancer Center with Professor Samuel Danishefsky. Wendy is listed as an inventor or author on over 65 patent and research publications and has given presentations at many national and international meetings. Wendy was recently elected as Vice Chair of the ACS Medicinal Chemistry (ACS MEDI) Division which will culminate in her being Chair of the Division in 2017.
Discovery and SAR of new Btk inhibitors that bind to the Btk ATP-binding cleft.
FromSpecific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis
- Nature Chemical Biology,7,41–50(2011)
- doi:10.1038/nchembio.481
(a) Library design and identification of CGI560 (1). (b) Structure of CGI1746 (2) and SAR for H3 binding. The amide motif and t-butylphenyl group are required for potent Btk inhibition. IC50s were determined at the Km for Btk and are the mean ± s.e.m. of at least three experiments. (c) Kinome binding map of CGI1746 based on an Ambit screen, data provided in Supplementary Table 2. CGI1746 only showed significant binding to Btk at 1 μM, indicated by the red circle.
.............................................
Project Details:
Highlights in Medicinal Chemistry - Short Course to postgraduate students of the summer school at the Federal University of Rio de Janeiro (UFRJ)
| Project No.: | 2014-022-1-700 |
| Start date: | 2014-09-01 |
| End date: | 0000-00-00 |
| Division: | Chemistry and Human Health Division |
The group during the Rio Summer School in Medicinal Chemistry (January 24-30, 2015); from left: A. Ganesan, Jan Heeres, Klaus Wanner, Joerg Senn-Bilfinger, Patrick Woster, Lidia M. Lima, Peter Bernstein, Eliezer J. Barreiro, Janos Fischer, Helmut Buschmann, Wendy Young, Tom Perun, and Carlos A.M. Fraga.
..........................................................
NOS 2015 Symposium University of Pennsylvania, 215-898-3048
https://www.organicdivision.org/ama/orig/NOS/speakers.html
|
|
| 44th NATIONAL ORGANIC CHEMISTRY SYMPOSIUM |
Wendy Young Genentech
...............
https://www.google.com.ar/patents/WO2010056875A1?cl=en
//////////Wendy Young, Vice President, Discovery Chemistry, Genentech
No comments:
Post a Comment